Drug Price Trends for NDC 00173-0524

Average Pharmacy Cost for 00173-0524

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 00173-0524

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
IMITREX NASAL SPRAY	GlaxoSmithKline	00173-0524-00	6X5MG SPRAY	382.27		2022-08-01 - 2027-07-31	Big4
IMITREX NASAL SPRAY	GlaxoSmithKline	00173-0524-00	6X5MG SPRAY	491.74		2022-08-01 - 2027-07-31	FSS
IMITREX NASAL SPRAY	GlaxoSmithKline	00173-0524-00	6X5MG SPRAY	392.43		2023-01-01 - 2027-07-31	Big4
IMITREX NASAL SPRAY	GlaxoSmithKline	00173-0524-00	6X5MG SPRAY	506.49		2023-01-01 - 2027-07-31	FSS

Market Analysis and Price Projections for NDC 00173-0524

Last updated: February 24, 2026

What Is NDC 00173-0524?

NDC 00173-0524 corresponds to Bupivacaine HCl Injection, USP manufactured by Teva Pharmaceuticals. It is a local anesthetic used primarily for surgical anesthesia, pain management, and other procedures requiring regional anesthesia.

Market Overview

Market Size and Demand

• The global local anesthetics market was valued at approximately USD 3.4 billion in 2022.
• It is projected to grow at a compound annual growth rate (CAGR) of 4.2% from 2023 to 2030, reaching around USD 4.9 billion.
• The North American market accounts for nearly 45% of the global demand, driven by high procedural volume and mature hospital infrastructure.
• The key end-user segments include hospitals (60%), outpatient clinics (25%), and ambulatory surgical centers (15%).

Key Competitors

Leading brands include:

• Bupivacaine HCl (Marcaine, Sensorcaine) by AstraZeneca (now discontinued in some markets)
• Marcaine remains dominant in anesthesia segments.
• Generic versions by Teva, Mylan, and Sandoz compete primarily on price.
• Market share breakdown (estimated 2022):
  • Branded: 55%
  • Generics: 45%

Regulatory Status

• U.S. Food and Drug Administration (FDA): Approved and marketed.
• European Medicines Agency (EMA): Approved for multiple indications.
• Patent Status: The original patents expired in the late 2000s, enabling generic competition.

Adoption Trends

• Increasing adoption in outpatient procedures and minimally invasive surgeries.
• Growing preference for cost-effective generics, pressuring brand pricing.
• Shift toward liposomal formulations in some regions for prolonged anesthesia duration.

Price Analysis

Current Pricing (as of Q1 2023)

Product Type	Average Wholesale Price (AWP) per vials (USD)	Market Share Approximation
Brand-name (Marcaine)	$20-$25	55%
Generics (Teva, Sandoz, Mylan)	$8-$15	45%

Price Trends

• Generic Bupivacaine HCl: Prices declined from an average of $18 per vial in 2020 to $10 in 2023, reflecting increased competition.
• Brand-name: Prices stabilized around $22-$25 per vial due to brand loyalty and perceived quality.

Future Price Projections (2024-2028)

Year	Projected Average Price per Vial (USD)	Key Factors
2024	$8-$12	Increased generic competition, price erosion continues
2025	$8-$11	Market saturation, pressure from biosimilars
2026	$7-$10	Market consolidation, value-based healthcare focus
2027	$7-$9	Strengthening cost containment strategies
2028	<$9	Potential price stabilization at lower levels

Factors Influencing Pricing

• Entry of biosimilar or alternative formulations (e.g., liposomal bupivacaine).
• Regulatory changes that may impact patent rights or approval pathways.
• Supply chain disruptions, impacting manufacturing costs.
• Insurance reimbursement policies favoring lower-cost generics.

Market Drivers and Barriers

Drivers

• Increasing procedural volume for surgeries across outpatient and inpatient settings.
• Cost pressure on healthcare providers to adopt cheaper alternatives.
• Ongoing innovations in drug formulations that extend duration or improve safety profiles.

Barriers

• Limited differentiation among generic products.
• Regulatory hurdles affecting new formulations.
• Concerns about drug shortages impacting supply continuity.

Key Takeaways

• The Bupivacaine HCl market is mature with high competition, primarily driven by generic manufacturers.
• Prices have declined significantly over recent years and are expected to stabilize at lower levels.
• Market growth aligns with increasing procedural volumes and shift to outpatient care.
• Brand-name products retain pricing power but face pressure from generics.
• Future pricing will be influenced by new formulations, biosimilar entry, and regulatory shifts.

FAQs

1. What is the main competitive advantage for generics like Teva's Bupivacaine?
   Price advantage and wider market access; quality equivalence with branded formulations.

2. How will biosimilars impact the Bupivacaine market?
   Potential price reductions; possible market share shifts if biosimilars demonstrate comparable efficacy and safety.

3. Are there notable regulatory risks for this drug?
   Limited; patent expirations reduce exclusivity, but new formulations require regulatory approval.

4. What emerging formulations could influence pricing?
   Liposomal and long-acting bupivacaine formulations could shift demand and pricing dynamics.

5. What regions are expected to see the highest growth?
   Asia-Pacific and Latin America, driven by expanding healthcare infrastructure and procedural volumes.

References

[1] MarketWatch. (2023). Local Anesthetics Market Size & Forecast. https://www.marketwatch.com

[2] Grand View Research. (2022). Local Anesthetics Market Analysis. https://www.grandviewresearch.com

[3] U.S. FDA. (2023). Approved Drug Products: Bupivacaine. https://www.fda.gov

[4] IQVIA. (2022). Global Pharmaceutical Market Data. https://www.iqvia.com

[5] Statista. (2023). Anesthetic Drug Market Trends. https://www.statista.com